Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVIVE: SurVaxM plus temozolomide as adjuvant therapy for newly diagnosed glioblastoma
CTR20222378Phase 2Active
- Sponsor
- ---/ 上海复星医药产业发展有限公司
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of SurVaxM in glioblastoma (GBM), sponsored by ---/ 上海复星医药产业发展有限公司. Started Sep 2022; status: active.
02
Drugs
SurVaxM
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20222378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222378.